



IPSEN CARES Enrollment Form

Please print the form, fill it out completely, sign it, and
FAX TO 1-888-525-2416

To be completed by patient and physician's office.

- HCP Injection Training Benefits Verification Only Nurse Home Health Administration Adherence Calls

PATIENT

Patient Name (First & Last) _____ Caregiver/Alternate Contact Phone # (____) _____
 Patient Address _____ Date of Birth (MM/DD/YY) ____/____/____ Male Female
 City _____ State _____ Zip _____ Email Address _____
 Caregiver/Alternate Contact Name _____ Home Phone # (____) _____ Other Phone # (____) _____
 Relationship of Caregiver/Alternative Contact to Patient _____ Preferred Language _____

INSURANCE

Complete or attach front and back copy of patient's primary and secondary insurance cards for pharmacy and medical benefits.
 Is patient insured? Yes No Medical Insurance Co. _____
 Does patient have secondary insurance? Yes No Insurance Co. Phone # (____) _____
 Pharmacy Insurance Co. _____ Subscriber Name _____ Policy ID # _____
 Insurance Co. Phone # (____) _____ Subscriber Policy ID # _____
 Is Physician a Participating Provider (check one) Participating Non-Participating
 Policy/Employer/Group # _____

PRESCRIBER

Prescriber Name _____ Street Address _____
 DEA # _____ State License # _____ City _____ State _____ Zip _____
 Tax ID # _____ NPI # _____ Office Contact and Title _____
 Medicaid Provider # (Required if Medicaid Patient) _____ Phone # (____) _____ Fax # (____) _____
 Medicare PTAN # (Required if Medicare Patient) _____ Email Address _____
 Office/Institution _____ Preferred Method of Contact Phone Fax Email
 Specialty Oncologist Endocrinologist Other _____

PRESCRIPTION

Somatuline® Depot (lanreotide) Injection

Indication	Strength	Frequency
<input type="checkbox"/> Acromegaly	<input type="checkbox"/> 60 mg <input type="checkbox"/> 90 mg <input type="checkbox"/> 120 mg	<input type="checkbox"/> 4 weeks <input type="checkbox"/> 6 weeks (extended dosing interval) <input type="checkbox"/> 8 weeks (extended dosing interval) <input type="checkbox"/> Other _____
<input type="checkbox"/> Gastroenteropancreatic neuroendocrine tumor (GEP-NET)	<input type="checkbox"/> 120 mg	<input type="checkbox"/> 4 weeks <input type="checkbox"/> Other _____
<input type="checkbox"/> Carcinoid Syndrome	<input type="checkbox"/> 120 mg	<input type="checkbox"/> 4 weeks <input type="checkbox"/> Other _____

Quantity _____ Number of Refills _____

Route: Deep Subcutaneous

Site of Care Physician Office Hospital/Outpatient Infusion Center Other _____
 Site of Injection Upper outer buttocks, rotate between sides Other _____
 Directions for Use _____

PRESCRIBER /OFFICE MANAGER ATTESTATION:

(The Prescriber must sign if this form is to be used as a prescription to be triaged to a Specialty Pharmacy, request for Injection Training, request for Home Health Administration (HHA) or to enroll a patient for free goods as part of the Patient Assistance Program (PAP). The office manager of the Prescriber may sign if the request is limited to Benefit Verification or Copay Assistance Support.)

By signing below, I certify that a prescription signed by a licensed prescriber is on file for the above therapy and that the patient named on this form has provided the necessary authorization to release the above referenced information and medical and/or patient information relating to Somatuline Depot therapy to Ipsen and its agents or contractors for the purpose of seeking reimbursement for Somatuline Depot therapy, assisting in initiating or continuing Somatuline Depot therapy, and/or evaluating the patient's eligibility for Ipsen's patient support programs administered by IPSEN CARES. I authorize Ipsen to be my agent and to forward the above prescription, by fax or other mode of delivery, to the pharmacy chosen by the patient named on this form. For the state of New York, copies of all prescriptions should be on official New York state prescription forms. I certify that any medications received from Ipsen in connection with any IPSEN CARES program will be used only for the named patient.

These medications will not be offered for sale, trade, or barter. Additionally, no claim for reimbursement will be submitted concerning these medications to any payor, including Medicare, Medicaid, or any other federal or state health insurance program, nor will any medications be returned for credit. If the named patient does not return for therapy, product will be returned to Ipsen. I acknowledge that I have assisted the patient in enrolling in IPSEN CARES exclusively for purposes of patient care and not in consideration for, expectation of, or actual receipt of remuneration of any sort.

Name _____ Title _____
 Signature _____ Date _____

Please see accompanying full Prescribing Information and Patient Information.

ACROMEGALY SECTION (If Applicable)

SOMATULINE® DEPOT (lanreotide) Injection is a somatostatin analog indicated for:

The long-term treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option; the goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal.

Have you documented that your patient has experienced an inadequate response to or cannot be treated with surgery and/or radiotherapy?
 Yes No

Diagnosis Acromegaly (ICD-10-CM Code) _____ Description _____

CPT Code _____ Description _____

Date of Diagnosis ____/____/____ Therapy Start Date ____/____/____

Have other products been used to treat this patient? Yes No Product _____ Date of Last Injection ____/____/____

Allergies No Known Drug Allergies List Allergies _____

List Medications _____

GEP-NET AND CARCINOID SYNDROME SECTION (If Applicable)

SOMATULINE® DEPOT (lanreotide) Injection is a somatostatin analog indicated for:

The treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival

The treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy

Diagnosis GEP-NETs (ICD-10-CM Code) _____ Description _____

Carcinoid Syndrome (ICD-10-CM Code) _____ Description _____

CPT Code _____ Description _____

Date of Diagnosis ____/____/____ Therapy Start Date ____/____/____

Have other products been used to treat this patient? Yes No Product _____ Date of Last Injection ____/____/____

Allergies No Known Drug Allergies List Allergies _____

List Medications _____

PATIENT SUPPORT

Would you like us to provide Temporary Patient Assistance if patient is eligible? Yes No

Would you like to request injection training and nursing support from an IPSEN CARES nurse for your staff? Yes No

If yes, requested location for training is Prescriber's Office Other MD Office/Clinic _____

Would you like to request nurse home health administration of Somatuline® Depot for your patient by an IPSEN CARES nurse if the patient is eligible? Yes No

SPECIALTY PHARMACY AND BUY & BILL

Are you going to utilize Specialty Pharmacy or Buy & Bill? Specialty Pharmacy Buy & Bill

Preferred Specialty Pharmacy _____

Was Rx sent to a Specialty Pharmacy already? Yes No If yes, please provide the name of the Specialty Pharmacy _____

INDICATIONS

SOMATULINE® DEPOT (lanreotide) Injection is a somatostatin analog indicated for:

- the long-term treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option; the goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal;
- the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and
- the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

IMPORTANT SAFETY INFORMATION

Contraindications

- SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.

Please see accompanying full Prescribing Information
and Patient Information.

IMPORTANT SAFETY INFORMATION, CONTINUED

Warnings and Precautions

- **Cholelithiasis and Gallbladder Sludge**
 - SOMATULINE DEPOT may reduce gallbladder motility and lead to gallstone formation.
 - Periodic monitoring may be needed.
- **Hypoglycemia or Hyperglycemia**
 - Pharmacological studies show that SOMATULINE DEPOT, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.
 - Blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.
- **Cardiovascular Abnormalities**
 - SOMATULINE DEPOT may decrease heart rate.
 - In cardiac studies with acromegalic patients, the most common cardiac adverse reactions were sinus bradycardia, bradycardia, and hypertension.
 - In patients in the GEP-NET pivotal trial, 23% of SOMATULINE DEPOT-treated patients had a heart rate of less than 60 bpm compared to 16% of placebo-treated patients. The incidence of bradycardia was similar in the treatment groups. Initiate appropriate medical management in patients with symptomatic bradycardia.
 - In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia. In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia.
- **Thyroid Function Abnormalities**
 - Slight decreases in thyroid function have been seen during treatment with lanreotide in acromegalic patients.
 - Thyroid function tests are recommended where clinically appropriate.
- **Monitoring/Laboratory Tests:** In acromegaly, serum GH and IGF-1 levels are useful markers of the disease and effectiveness of treatment.

Adverse Reactions

- **Acromegaly:** Adverse reactions occurring in greater than or equal to 9% of patients who received SOMATULINE DEPOT in the overall pooled safety studies in acromegaly were diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), and injection-site reactions (9%).
- **GEP-NETs:** Adverse reactions occurring in greater than 10% of patients who received SOMATULINE DEPOT in the GEP-NET trial were abdominal pain (34%), musculoskeletal pain (19%), vomiting (19%), headache (16%), injection site reaction (15%), hyperglycemia (14%), hypertension (14%), and cholelithiasis (14%).
- **Carcinoid Syndrome:** Adverse reactions occurring in the carcinoid syndrome trial were generally similar to those in the GEP-NET trial. Adverse reactions occurring in greater than 5% of patients who received SOMATULINE DEPOT in the carcinoid syndrome trial and occurring at least 5% greater than placebo were headache (12%), dizziness (7%) and muscle spasm (5%).

Drug Interactions: SOMATULINE DEPOT may decrease the absorption of cyclosporine (dosage adjustment may be needed); increase the absorption of bromocriptine; and require dosage adjustment for bradycardia-inducing drugs (e.g., beta-blockers).

Special Populations

- **Lactation:** Advise women not to breastfeed during treatment and for 6 months after the last dose.
- **Moderate to Severe Renal and Hepatic Impairment:** See full prescribing information for dosage adjustment in patients with acromegaly.

To report **SUSPECTED ADVERSE REACTIONS**, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information
and Patient Information.

IPSEN CARES[®]
Coverage. Access. Reimbursement & Education Support



Somatuline[®] Depot
(lanreotide) Injection 60mg 90mg 120mg

Please print the form, sign it, and fax it to IPSEN CARES at the number above, or send the form to:

IPSEN CARES Program
Ipsen Biopharmaceuticals, Inc.
11800 Weston Parkway
Cary, NC 27513

Patient Authorization

Patient Authorization and Signature - IPSEN CARES[®] Program

I authorize my healthcare providers (including those pharmacies that may receive my prescription for Somatuline Depot), to disclose personal health information ("PHI") about me, including health information relating to my medical condition, prescription, and insurance coverage, to Ipsen Biopharmaceuticals, Inc., its affiliates, and its agents that have been hired to administer the Ipsen Coverage, Access, Reimbursement & Education Support (IPSEN CARES) program on its behalf (collectively, "Ipsen") in order for Ipsen to (1) enroll me in IPSEN CARES; (2) establish my benefit eligibility and potential out-of-pocket costs for Somatuline Depot; (3) communicate with my healthcare providers and health plans about my treatment plan; (4) provide support services including patient education and financial assistance for Somatuline Depot; (5) help get Somatuline Depot shipped to me or my healthcare providers; (6) evaluate my eligibility for home health administration if requested by my physician; and (7) facilitate my participation in Somatuline Depot patient programs that I have elected to receive information about, as indicated below. I agree that, using the contact information I provide, Ipsen may contact me for reasons related to the IPSEN CARES program and support services and may leave messages for me that may disclose that I am on Somatuline Depot therapy. I consent to being contacted by an IPSEN CARES program representative in order for the program to obtain further information or clarification regarding any adverse event I may experience.

I understand that once my PHI has been disclosed to Ipsen, it is no longer protected by federal privacy laws and Ipsen may re-disclose it; however, Ipsen has agreed to protect my PHI by using and disclosing it only for the purposes described above or as required by law. I understand that my healthcare providers may receive remuneration from Ipsen in exchange for my PHI and/or for any therapy support services provided to me.

I can withdraw this authorization by calling IPSEN CARES at 1-866-435-5677 or mailing a letter requesting such revocation to IPSEN CARES, 11800 Weston Parkway, Cary, NC 27513, but it will not change any actions taken before I withdraw authorization. Withdrawal of authorization will end further uses and disclosures of PHI by the parties identified in this form except to the extent those uses and disclosures have been made in reliance upon my authorization. I understand that I may refuse to sign this form and, if I do so, I will not be able to participate in IPSEN CARES programs, but it will not affect my eligibility to obtain medical treatment, my ability to seek payment for this treatment or affect my insurance enrollment or eligibility for insurance coverage. This authorization expires one year after the date I sign it below. I understand that I will receive a copy of the signed authorization.

Patient Name _____ Parent/Legal Guardian _____
Name _____ Relationship to Patient _____
Signature _____ Date _____
Patient Date of Birth _____ Patient Phone Number _____

Please See Next Page for Important Safety Information and the accompanying full Prescribing Information and Patient Information. Questions? Call IPSEN CARES at 1-866-435-5677

IPSEN CARES[®]
Coverage. Access. Reimbursement & Education Support

What is SOMATULINE® DEPOT (lanreotide) Injection?

SOMATULINE DEPOT is a prescription medicine used in adults for:

- the long-term treatment of people with acromegaly when surgery or radiotherapy have not worked well enough or a patient is unable to have surgery or radiotherapy;
- the treatment of a type of cancer known as neuroendocrine tumors, from the gastrointestinal tract or the pancreas (GEP-NETs) that has spread or cannot be removed by surgery; and
- the treatment of carcinoid syndrome to reduce the need for the use of short-acting somatostatin medicine.

It is not known if SOMATULINE DEPOT is safe and effective in children.

IMPORTANT SAFETY INFORMATION

- **Do not take SOMATULINE DEPOT** if you are allergic to lanreotide.
- **SOMATULINE DEPOT may cause serious side effects**, including:
 - Gallstones
 - Changes to blood sugar (high or low blood sugar),
 - Slow heart rate, and
 - High blood pressure, and
 - Changes in thyroid function in acromegaly patients.

Tell your healthcare provider (HCP) if you have any of the following symptoms:

- **Symptoms of gallstones** may include sudden pain in your upper right stomach area (abdomen), sudden pain in your right shoulder or between your shoulder blades, yellowing of your skin and whites of your eyes, fever with chills, and nausea.
- **Symptoms of high blood sugar** may include increased thirst, increased appetite, nausea, weakness or tiredness, urinating more than normal, and fruity smelling breath.
- **Symptoms of low blood sugar** may include dizziness or lightheadedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, irritability or mood changes, and hunger.
- **Symptoms of slow heart rate** may include dizziness or lightheadedness, fainting or near-fainting, chest pain, shortness of breath, confusion or memory problems, and weakness or extreme tiredness.
- SOMATULINE DEPOT can cause the thyroid gland to not make enough thyroid hormone in people with acromegaly. Symptoms of low thyroid levels may include fatigue, weight gain, puffy face, being cold all the time, constipation, dry skin, thinning or dry hair, decreased sweating, and depression.
- **The most common side effects of SOMATULINE DEPOT in people with:**
 - **Acromegaly:** diarrhea; stomach (abdominal) pain; nausea; pain, itching, or a lump at the injection site
 - **GEP-NETs:** stomach area (abdominal) pain; muscle and joint aches; vomiting; headache; pain, itching or a lump at the injection site
 - **Carcinoid syndrome:** headache, dizziness, muscle spasm; side effects were generally similar to those commonly seen with GEP-NETs
- SOMATULINE DEPOT may cause dizziness. If this happens, do not drive a car or operate machinery.
- Tell your HCP right away if you have signs of an allergic reaction after receiving SOMATULINE DEPOT, including swelling of your face, lips or tongue; breathing problems; fainting, dizziness or feeling lightheaded (low blood pressure); itching; skin flushing or redness; rash; or hives.
- **Before taking SOMATULINE DEPOT, tell your HCP about all your medical conditions including if you:** have diabetes; have gallbladder, heart, thyroid, kidney or liver problems; are pregnant or plan to become pregnant; or are breastfeeding or plan to breastfeed. It is not known if SOMATULINE DEPOT will harm your unborn baby or pass into breast milk. You should not breastfeed if you receive SOMATULINE DEPOT and for 6 months after your last dose. SOMATULINE DEPOT may affect your ability to become pregnant.
- **Tell your HCP about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SOMATULINE DEPOT and other medicines may affect each other, causing side effects. SOMATULINE DEPOT may affect the way other medicines work, and other medicines may affect how SOMATULINE DEPOT works. Your dose of SOMATULINE DEPOT or your other medications may need to be changed. If you have diabetes, your HCP may change your dose of diabetes medication when you first start receiving SOMATULINE DEPOT or if your dose of SOMATULINE DEPOT is changed.
- **Especially tell your HCP if you take:**
 - Insulin or other diabetes medicines,
 - A cyclosporine (Gengraf, Neoral, or Sandimmune), or
 - Medicines that lower your heart rate, such as beta blockers.

Know the medicines you take. Keep a list of them to show your HCP when you get a new medicine.

Tell your HCP if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of SOMATULINE DEPOT. For more information, ask your HCP.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full [Prescribing Information](#) and [Patient Information](#). Questions? Call IPSEN CARES® at 1-866-435-5677

IPSEN CARES®
Coverage. Access. Reimbursement & Education Support

Additional Product and Support Information

- I agree to be contacted by autodialed text messages (“texts”) at the mobile phone number I have provided below for the purpose of helping me/the patient stay on therapy, which may promote or advertise the Ipsen products included in the therapy plan. I certify that the number I am providing belongs to me and not a family member or third party. I understand that I may opt out of individual communications of the program entirely at any time by calling 866-435-5677 or replying “STOP” by text to any text from Ipsen. Ipsen will not sell or rent this information and will use it only in accordance with this authorization and consent. Consent to being contacted by text messages is not a condition of participation in the IPSEN CARES® programs or the purchase of any products or services. I understand that my cellular service carrier’s data and text messaging rates may apply. Privacy policy at www.ipsencares.com. This authorization is valid for one year from the date the form is signed. If I am providing this consent on behalf of another person, I certify that I am authorized to agree to every element of this consent on behalf of such other person, and I agree that I will be liable and will hold Ipsen harmless in the event that such other person alleges that they did not give consent.

- In addition to participating in the IPSEN CARES program above, I would also like to receive information from Ipsen via text message and voice call, all of which may include telemarketing, advertisements, and educational material about SOMATULINE DEPOT and programs that support patients. These text messages and voice calls may be made via the use of automatic telephone dialing systems. I certify that the number I am providing belongs to me and not to a family member or other third party. I understand that I do not have to sign this section of the form in order to participate in the IPSEN CARES program and that I may revoke this authorization to receive additional product information at any time. By signing below, I agree that Ipsen and its agents may use and disclose my personal information (including name, address, phone number, and/or email) to provide these services and Ipsen may also contact me to solicit my opinions regarding SOMATULINE DEPOT and Ipsen’s products and services. I understand that my cell phone carrier’s standard rates may apply for calls to my cell phone. This authorization is valid for one year from the date the form is signed. I may revoke this authorization, by calling 866-435-5677 or sending a request in writing to: IPSEN CARES, 11800 Weston Parkway, Cary, NC 27513. If I am providing this consent on behalf of another person, I certify that I am authorized to agree to every element of this consent on behalf of such other person, and I agree that I will be liable and will hold Ipsen harmless in the event that such other person alleges that they did not give consent.

Patient Name _____ Parent/Legal Guardian _____

Name _____ Relationship to Patient _____

Signature _____ Date _____



Somatuline[®] Depot
(lanreotide) Injection 60 mg 90 mg 120 mg

Somatuline Depot is a registered trademark of IPSEN PHARMA S.A.S.
IPSEN CARES is a registered trademark of Ipsen S.A.
©2019 Ipsen Biopharmaceuticals, Inc. January 2019 SMD-US-002726

IPSEN CARES[®]
Coverage. Access. Reimbursement & Education Support